# Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian Cancer

> **NCT00016224** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center**

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** thalidomide

## Key facts

- **NCT ID:** NCT00016224
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-01
- **Primary completion:** 2004-03
- **Final completion:** 2004-03
- **Target enrollment:** — (—)
- **Last updated:** 2013-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00016224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00016224, "Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00016224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*